Lipids |
|
|
|
LXA4 |
|
|
|
|
|
Virus |
|
|
Downregulation of LXA4 levels in vitro. Exogenous LXA4 reduced
the activation of ERK, NF-κB, and AKT pathways |
Kaposi’s
sarcoma-associated herpesvirus (KSHV) |
Chandrasekharan et al.,
2016 |
|
Possible downregulation LXA4 levels to modulate chromatin dynamics and
favours viral cycle |
Kaposi’s sarcoma-associated herpesvirus (KSHV) |
Asha et al., 2020 |
|
|
Respiratory sincicial virus (RSV) |
Shirei et al.,
2014 |
|
Lower LXA4/LTB4 ratio during co-infection |
RSV and Micoplasma
pneumoniae co-infection |
Wu et al., 2016 |
|
Increase in LXA4 levels in human monocytes |
Human immunodeficiency
virus (HIV) |
Genis et al., 1992 |
|
Decreased levels of LXA4 in Gx KO infected mice |
Influenza A virus
(IAV) |
Kelvin et al., 2014 |
|
Marked increase in LXA4 levels in the BAL fluid of COVID-19 patients |
SARS-CoV-2 |
Archambault et al., 2021 |
|
|
Bacteria |
|
|
Elevated plasma levels of LXA4 in active tuberculosis patients
compared with latently infected individuals and healthy volunteeers at
diagnosis |
Mycobacterium tuberculosis |
Nore et al., 2020; Lee
et al., 2015; Kumar e tal, 2019 |
|
Virulent strains of M. tuberculosis stimulate production of LXA4,
playing a deleterious effect via consequent reduction of PGE2 |
Mycobacterium tuberculosis |
Chen et al., 2008; Divangahi et al.,
2009 |
|
Increased LXA4 levels and decreased survival and host cell death |
Pseudomonas aureoginosa |
Dar et al., 2022 |
|
Bacterial epoxide hydrolase decreased the levels of 15-Epi-LXA4
synthesis and enhances inflammation in the BAL fluid of patients as well
as in mice |
Pseudomonas aureoginosa |
Flitter et al., 2017
Hvorecny et al., 2018 |
|
Time-dependent production of LXA4 and FPR2 expression in the human
skin |
Escherichia coli |
Motwani et al., 2018 |
|
|
Brucella abortus |
Fahel et al., 2015 |
|
Disturbed levels of LXA4 in the human placenta during infection |
Listeria monocytogenes |
Conner et al., 2022 |
|
Disturbed levels of LXA4 in nasal polyps |
Staphylococcus
aureus |
Pérez-Novo et al., 2006 |
Resolvins (D, E, and T series) |
|
|
|
|
|
Virus |
|
|
Downregulation of RvD1 and RvD3 in the plasma of critically ill
COVID-19 patients. Correlation between decreased levels and severity of
disease |
SARS-CoV-2 |
Palmas et al., 2021 |
|
Higher levels of RvD1, D2, D4 and D5 in the BAL fluid COVID-19
patients when compared th healthy individuals |
SARS-CoV-2 |
Archambault
et al., 2021 |
|
Diminished levels of RvD1 in the plasma in humans |
Clostridium
difficile |
Dróżdż et al., 2020 |
|
Diminished levels of RvD1 in the serum of patients with Hansen’s
disease |
Mycobacterium leprae |
Silva et al.,
2017 |
Maresins |
|
Virus |
|
|
Increased levels of Mar-1 and Mar-2 in the serum of COVID-19 patients
when compared to control individuals |
SARS-CoV-2 |
Regidor et al.,
2021 |
α-MSH |
|
|
|
|
|
Bacteria |
|
|
Cleavage of α-MSH by toxins produced by S. aureus
|
Staphylococcus aureus |
Rago et al., 2000 |
|
Higher levels of α-MSH in the blood of HIV patients correlated with
reduced progression of disease |
HIV |
Catania et al., 1993; Airaghi et
al., 1999; Catania et al., 1994 |
GILZ |
|
|
|
|
|
Virus |
|
|
IBDV prevented GILZ degradation |
Infectious bursal disease virus
(IBDV) |
He et al., 2018; Li et al., 2013 |
|
NS1 protein of RSV decreased the levels of GILZ in A549 cells |
RSV |
Marketon et al., 2014 |
|
|
Bacteria |
|
|
Up-regulation of GILZ levels by Yersinia enterocolitica and
Clostridium difficile in vitro
|
Yersinia
enterocolitica and Clostridium difficile
|
Köberle et al.,
2012 |
|
Lower expression of GILZ in monocytes from septic patients |
Septic
shock |
Ellouze et al., 2020 |
|
Increased expression of GILZ restricted to macrophages |
CLP model |
Ellouze et al., 2020 |
AnxA1 |
|
Parasite |
|
|
Enhanced levels of AnxA1 in the spleen of infected mice |
Schistosoma japonicum |
Burke et al., 2010 |
|
Enhanced levels of AnxA1 in the cytoplasm of liver cells of golden
hamsters |
Opisthorchis viverrini |
Hongsrichan et al.,
2014 |
|
Increased levels of AnxA1 in human neutrophils and RPE cells |
Toxoplasma gondii |
Mimura et al., 2012 |
|
|
Bacteria |
|
|
Up-regulated levels of AnxA1 in both skin and serum of patients |
Mycobacterium leprae |
Ribeiro et al., 2020 |
|
Perturbed levels of AnxA1 in MDSCs of infected patients |
Mycobacterium leprae |
da Silva et al., 2021 |
|
Increase of AnxA1 levels during Rolipram + antibiotics treatment |
Streptococcus pneumoniae |
Tavares et al., 2016 |
|
|
Virus |
|
|
Decreased levels of AnxA1 in the plasma of COVID-19 patients |
SARS-CoV-2 |
Canacik et al., 2020 |
|
increased levels of severe COVID-19 patients compared to mild patients |
SARS-CoV-2 |
Ural et al., 2022 |
|
Increased expression levels of AnxA1 in circulating monocytes of
COVID-19 convalescent patients |
SARS-CoV-2 |
Wen et al.,
2020 |
|
H1N1 infection up-regulates FPR2 expression in vitro
|
H1N1 |
Ampomah et al., 2018 |